November 30, 2016 / 12:42 PM / in 10 months

BRIEF-Helix Biopharma Corp accelerates escalation of l-dos47 dosing in the U.S. early-stage study

Nov 30 (Reuters) - Helix Biopharma Corp -

* Helix Biopharma Corp accelerates escalation of l-dos47 dosing in the U.S. Phase I study

* FDA accepted accelerated escalation scheme for l-dos47 dosing in U.S. Phase I study (ldos001) up to 12g/kg with pemetrexed/carboplatin Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below